Publication: Overcoming multidrug resistance in human lung cancer with novel benzo[a]quinolizin-4-ones
1
Issued Date
2011-03-01
Resource Type
ISSN
02507005
Other identifier(s)
2-s2.0-79956147268
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Anticancer Research. Vol.31, No.3 (2011), 921-927
Suggested Citation
Yodsoi Kanintronkul, Rattana Worayuthakarn, Nopporn Thasana, Pakorn Winayanuwattikun, Kovit Pattanapanyasat, Rudee Surarit, Somsak Ruchirawat, Jisnuson Svasti Overcoming multidrug resistance in human lung cancer with novel benzo[a]quinolizin-4-ones. Anticancer Research. Vol.31, No.3 (2011), 921-927. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/11585
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Overcoming multidrug resistance in human lung cancer with novel benzo[a]quinolizin-4-ones
Abstract
Aim: To investigate the ability of synthetic benzo[a]quinolizin-4-one derivatives to reverse multidrug resistance (MDR) in lung cancer cells. Materials and Methods: A cell line with MDR, A5 49RT-eto, was established by exposure to 1.5 μM etoposide. Cytotoxic activity was assayed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromine (MTT) method. The mechanism of drug resistance was studied by real-time PCR, Western blot analysis, and flow cytometry. Benzo[a] quinolizin-4-one derivatives were synthesized and tested for cytotoxic activity and ability to modulate MDR. Results: A549RT-eto cells had an IC 50 for etoposide of 176 μM, 28-fold higher than parental cells, due to increased levels of MDR1 gene and P-glycoprotein (P-gp), resulting in greater drug efflux. Three benzo[a]quinolizin-4-ones reduced etoposide IC 50 from 176 μM to 22.4 μM -24.7 μM. This resulted from increased drug accumulation without altering P-gp expression at the transcription or translation level. Conclusion: Non-toxic concentrations of benzo[a]quinolizin-4-one derivatives can reverse drug resistance of A549RT-eto by increasing the intracellular drug accumulation.